Announcement of Basic Agreement on Business Partnership with Kojin Bio Co., Ltd. for Product Development

We are pleased to announce that we have entered into a basic agreement on a business partnership with Kojin Bio Co., Ltd. (TSE Growth 177A, President: Takahito Nakamura) for “the development of animal iPS cell-derived regenerative medicine and related research-use products.”

Kojin Bio is a leading company in the regenerative medicine field, expanding its business domestically and internationally through the unique development of cell culture media and contract services for cell processing. Additionally, the company has engaged in pioneering research efforts in the field of veterinary medicine.

Through this partnership, we accelerate research and development, promote the manufacturing of higher-quality product, and expedite the early acquisition of marketing approval of our cell therapy product to achieve our goal of “global-standard animal regenerative medicine.” Furthermore, we collaborate with Kojin Bio to develop various animal iPS cell-derived cells for the purpose of basic research with their accumulated expertise.

Please refer to the PDF below for further details. (JAPANESE language only)